
    
      This is a second line open-labeled pilot phase 2 study in subjects with glioblastoma whose
      tumors have progressed following prior treatment with surgery, radiation and Temozolomide.
      Patients who have received avastin as a second-line treatment are not eligible for this
      study.
    
  